Increased risk for invasive breast cancer associated with hormonal therapy: A nation-wide random sample of 65,723 women followed from 1997 to 2008

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lai, Jung Nien ^a,b   Wu, Chien Tung ^b   Chen, Pau Chung ^c   Huang, Chiun Sheng ^d,e   Chow, Song Nan ^e   Wang, Jung Der ^c,f,g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; BREAST TUMOR; COHORT ANALYSIS; HORMONE SUBSTITUTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; TAIWAN;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TAIWAN; YOUNG ADULT;

EID: 80053614843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025183     Document Type: Article

References (30)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
2. Beral V, (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427.
3. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, et al. (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100: 2328-2337.
4. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, et al. (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.
5. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, et al. (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109: 721-727.
6. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.
7. Pedersen AT, Ottesen B, (2003) Issues to debate on the Women's Health Initiative (WHI) study. Epidemiology or randomized clinical trials-time out for hormone replacement therapy studies? Hum Reprod 18: 2241-2244.
8. Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK, (2005) Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 52: 264-276.
9. Adlercreutz H, (2002) Phyto-oestrogens and cancer. Lancet Oncol 3: 364-373.
10. Chen SB, Liu HP, Tian RT, Yang DJ, Chen SL, et al. (2006) High-performance thin-layer chromatographic fingerprints of isoflavonoids for distinguishing between Radix Puerariae Lobate and Radix Puerariae Thomsonii. J Chromatogr A 1121: 114-119.
11. Lau WS, Chen WF, Chan RY, Guo DA, Wong MS, (2009) Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells. Br J Pharmacol 156: 1136-1146.
12. Hu C, Liu H, Du J, Mo B, Qi H, et al. (2009) Estrogenic activities of extracts of Chinese licorice (Glycyrrhiza uralensis) root in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 113: 209-216.
13. Piersen CE, (2003) Phytoestrogens in botanical dietary supplements: implications for cancer. Integr Cancer Ther 2: 120-138.
14. Lee SH, Jung BH, Kim SY, Chung BC, (2004) Determination of phytoestrogens in traditional medicinal herbs using gas chromatography-mass spectrometry. J Nutr Biochem 15: 452-460.
15. Druss BG, Rosenheck RA, (1999) Association between use of unconventional therapies and conventional medical services. JAMA 282: 651-656.
16. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, et al. (2008) The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf 17: 609-619.
17. Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, et al. (2010) Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer 116: 3215-3223.
18. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, et al. (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56: 168-183.
19. Kuo DJ, Lee YC, Huang WF, (2007) Hormone therapy use and prescription durations of menopausal women in Taiwan: a 5 years' National Cohort study. Maturitas 58: 259-268.
20. Bush TM, Bonomi AE, Nekhlyudov L, Ludman EJ, Reed SD, et al. (2007) How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J Gen Intern Med 22: 1311-1316.
21. Weissmann-Brenner A, Brenner B, Sulkes J, Kaplan B, (2010) Women gynecologists' attitude toward their own health. Med Sci Monit 16: PH35-39.
22. Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, et al. (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28: 2690-2697.
23. Lyytinen H, Pukkala E, Ylikorkala O, (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108: 1354-1360.
24. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, et al. (2010) Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95: s1-s66.
25. Cust MP, (2007) Changes in practice since the publication in 2007 of further results from the Women's Health Initiative and the Million Women Study. Menopause Int 13: 141-143.
26. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491.
27. Government Information Office (2004) Taiwan Yearbook 2004. Taipei, Taiwan.
28. National Health Research Institutes (2003) National Health Insurance Research database.
29. Centers for Disease Control and Prevention (1979) International Classifi cation of Diseases, Ninth Revision (ICD-9). Atlanta, Georgia.
30. Amato P, Christophe S, Mellon PL, (2002) Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 9: 145-150.